Evidence map›Paper›PMID 24022237›Full record

Trial reportPsychopharmacology2014

The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree?

C Quisenaerts, M Morrens, W Hulstijn, E de Bruijn, M Timmers, J Streffer, J De la Asuncion, G Dumont, B Sabbe

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. A review of the effects of nicotine on social functioning.Experimental and clinical psychopharmacology · 2018
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

C Quisenaerts
M Morrens
W Hulstijn
E de Bruijn
M Timmers
J Streffer
J De la Asuncion
G Dumont
B Sabbe

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleCognitive symptoms have increasingly been recognized as an important target in the development of future treatment strategies in schizophrenia. The nicotinergic neurotransmission system has been suggested as a potentially interesting treatment target for these cognitive deficits. However, previous research yielded conflicting results, which may be explained by several methodological limitations, such as the failure to include both a group of smoking and non-smoking schizophrenic patients, the use of only a single nicotine dose, and the inclusion of a very limited cognitive battery.

objectivesThe present study aims at investigating the cognitive effects of nicotine in schizophrenia while addressing these methodological issues.

methodsIn a double-blind placebo-controlled randomized crossover design, cognitive effects are assessed in smoking (n =16) and non-smoking (n =16) schizophrenic patients after receiving active (1 or 2 mg) or placebo oromucosal nicotine spray.

resultsA modest improving effect of nicotine on attention in the smoking but not the non-smoking group was found. No enhancing effects were found on measures of visual memory, working memory, processing speed, psychomotor speed, or social cognitive functioning in either patient group.

conclusionsThese findings suggest that the nicotinic receptor only has limited value as a cognitive treatment target in schizophrenia.

Indexed as

Schizophrenic PsychologyAdultCognition DisordersCross-Over StudiesDouble-Blind MethodFemaleHumansLinear ModelsMaleNeuropsychological TestsNicotineNicotinic AgonistsNootropic AgentsPsychomotor PerformanceSchizophreniaSmokingNicotineNicotinic AgonistsNootropic Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.